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Reference values of whole-blood fatty acids by age
and sex from European children aged 3–8 years
M Wolters1, H Schlenz1, R Foraita1, C Galli2, P Risé2, LA Moreno3, D Molnár4, P Russo5, T Veidebaum6, M Tornaritis7, K Vyncke8, G Eiben9,
L Iacoviello10,11 and W Ahrens1,12 on behalf of the IDEFICS consortium
OBJECTIVES: To establish reference values for fatty acids (FA) especially for n-3 and n-6 long-chain polyunsaturated FAs (LC PUFA)
in whole-blood samples from apparently healthy 3–8-year-old European children. The whole-blood FA composition was analysed
and the age- and sex-speciﬁc distribution of FA was determined.
DESIGN AND SUBJECTS: Blood samples for FA analysis were taken from 2661 children of the IDEFICS (identiﬁcation and prevention
of dietary- and lifestyle-induced health effects in children and infants) study cohort. Children with obesity (n= 454) and other
diseases that are known to alter the FA composition (n= 450) were excluded leaving 1653 participants in the reference population.
MEASUREMENTS: The FA composition of whole blood was analysed from blood drops by a rapid, validated gas chromatographic
method.
RESULTS: Pearson correlation coefﬁcients showed an age-dependent increase of C18:2n-6 and a decrease of C18:1n-9 in a
subsample of normal weight boys and girls. Other signiﬁcant correlations with age were weak and only seen either in boys
or in girls, whereas most of the FA did not show any age dependence. For age-dependent n-3 and n-6 PUFA as well as for other FA
that are correlated with age (16:0, C18:0 and C18:1n-9) percentiles analysed with the general additive model for location scale and
shape are presented. A higher median in boys than in girls was observed for C20:3n-6, C20:4n-6 and C22:4n-6.
CONCLUSIONS: Given the reported associations between FA status and health-related outcome, the provision of FA reference
ranges may be useful for the interpretation of the FA status of children in epidemiological and clinical studies.
International Journal of Obesity (2014) 38, S86–S98; doi:10.1038/ijo.2014.139
INTRODUCTION
Fatty acids (FA) not only serve as major substrates for energy
production but also fulﬁl several physiological functions. In this
respect, the main focus is on polyunsaturated fatty acids (PUFA)
such as alpha-linolenic acid (C18:3n-3) and linoleic acid (C18:2n-6)
and, particularly, on long-chain PUFA (LC PUFA) such as
eicosapentaenoic acid (C20:5n-3) and docosahexaenoic acid
(C22:6n-3) of the n-3 series and arachidonic acid (C20:4n-6) of
the n-6 series. LC PUFA have a major role in the structure and
function of cell membranes inﬂuencing their ﬂuidity and
permeability. In addition, they serve as precursors for the
production of eicosanoids, such as prostaglandins, leukotrienes
and thromboxanes, and docosanoids such as D-series resolvins
and protectins with various effects, for example, on vasodilation,
platelet aggregation, inﬂammation, cell growth and cell
proliferation.1 As a result LC PUFA inﬂuence normal growth,
neurological and visual development as well as cognitive and
immune function. Thus, an adequate status of LC PUFA is
especially important in children.
The blood FA composition reﬂects the dietary fat intake,2
especially LC n-3 PUFA are strongly correlated with intake.3,4 This
is why impaired PUFA availability may occur in children with
unbalanced diet, malabsorption or maldigestion syndrome5 and
diseases of the liver where chain elongation and desaturation of
LC PUFA are mainly located.6,7 Beyond limited bioavailability and
metabolism, monitoring of the blood FA becomes increasingly
important because a vast number of studies have reported a
modiﬁed blood PUFA distribution in various diseases. In particular,
the most common chronic childhood diseases8,9 in western
countries, for example, asthma,10–12 cystic ﬁbrosis,13,14 obesity,15,16
diabetes,17,18 mental health problems especially depression19,20
and attention-deﬁcity/hyperactivity disorders (ADHD)21,22 are
associated with modiﬁcations of the blood FA composition.
Moreover, some studies have shown signiﬁcant associations
between the disease outcome and the LC PUFA proﬁle, indicating
beneﬁcial effects of n-3 LC PUFA. Recently, it has also been shown
that the serum cholesterylester FA proﬁle in childhood is
associated with the carotid intima media thickness in adult
females23 and with blood pressure in males and, to a lesser extent,
also in females.24 Besides dietary intake, the activity of the
enzymes involved in the conversion of FA to LC PUFA, delta-9
desaturase (stearoyl-CoA desaturase1, SCD-1), delta-6 desaturase
(D6D) and delta-5 desaturase (D5D), also have an important role
for the FA composition because they are rate limiting in the
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biosynthesis of monounsaturated FA and LC PUFA. A high SCD-1
index has shown to be associated with obesity, whereas the D5D
and D6D indices are associated with insulin sensitivity and
metabolic syndrome.15,25,26
Whereas national data on the blood FA composition of young
children stem mainly from small and a few large study
populations,27–29 international data from unselected populations
are missing. Therefore, we aim to establish reference values for
3–8-year-old European children.
SUBJECTS AND METHODS
Subjects
A subsample of the IDEFICS (identiﬁcation and prevention of dietary- and
lifestyle-induced health effects in children and infants) cohort was included
in this study. In IDEFICS, 16 228 children aged 2–9 years were examined in
a population-based baseline survey in eight European countries ranging
from North to South and from East to West (Belgium, Cyprus, Estonia,
Germany, Hungary, Italy, Spain and Sweden) from autumn 2007 to spring
2008. This baseline survey (T0) was the starting point of the prospective
cohort study with the largest European children’s cohort established to
date.30 Additional 2517 children aged 2.0–10.9 years were newly recruited
during a second survey (T1) 2 years later; the study design has been
described in detail elsewhere.30 A subsample of the T0 and T1 IDEFICS
cohort is included in the present analysis.
Inclusion and exclusion criteria for reference population
FA composition was analysed in a subsample of IDEFICS participants with
oversampling of overweight and obese children. Therefore, weights were
constructed as described in the section ‘Statistical methods’. The reasons
for oversampling were the focus of the IDEFICS study on overweight and
obesity and a planned nested case–control study. Overall 2661 FA proﬁles
from fasting blood samples of children aged 2.0–10.9 years were analysed.
Of these, 1008 children were excluded for various reasons (Figure 1): 454
were deﬁned as obese according to Cole and Lobstein31 and 450 children
had other diagnosed diseases (allergies, asthma, major dermatological
problems, chronic rheumatic disease and diabetes mellitus) that may
inﬂuence the FA composition. In addition, the upper and lower age strata
included too few children for the analysis leaving 1653 participants aged
3.0–8.9 years in our analysis group.
Blood FA sampling and analysis
Blood samples were obtained by collecting a drop of blood from a
ﬁngertip or by venipuncture. A drop of native blood was then applied
directly to a test strip prepared with butylated hydroxytoluene as an
antioxidant. The dried strip was placed in a plastic envelope and shipped
to the laboratory. FA in blood lipids were separated and determined by
gas–liquid chromatography after direct derivatisation to their methyl
esters without prior extraction of total lipids from the samples as
previously described.32 In brief, the strip of paper was transferred to
Teﬂon screw-capped glass vials with 1ml 3 N MeOH/HCl and placed in a
dry bath at 90 °C for 1 h. Afterwards, 2 ml of water and 2ml of a saturated
KCl solution were added and FA methyl esters were then extracted using
2ml of n-hexane twice. After centrifugation (1000 g for 5 min at 4–5 °C),
the FA methyl esters recovered in the upper n-hexane phase were dried
under nitrogen ﬂow and vacuum by evaporating the solvent (n-hexane),
then they were redissolved in about 50 μl n-hexane and taken up. Finally,
1/100th volume was injected in a gas–liquid chromatography (model
GC1000, DANI Instruments SpA, Cologno Monzese, Italy) equipped with a
capillary column with 30m length, 0.32mm inner diameter and 0.25 μm
ﬁlm thickness in poly-ethylene-glycol (Omegawax 320 Supelco, Bellefonte,
PA, USA), a programmed temperature vaporising injector and a ﬂame
ionisation detector to quantify individual FA methyl esters, and a dedicated
data system. Temperature programming went from 120 °C for 1.20min,
with an increase of 2.7 °C per min to 205 °C, a 15-min hold period, then
with an increment of 5 °C per min to 220 °C and a 15-min hold period. For
identiﬁcation of the peaks pure reference compounds were used.
Basic study population
n=18 745
FA analysis  
n=2 661 
Exclusion because of 
• non-fasting n=12
• disease n=450
• obesity n=454
• unsufficient sample
size of age < 3 years 
and age
n=92 
Reference population
n=1 653
 9 years 
Figure 1. Flow chart of subject inclusion and exclusion.
Table 1. Basic characteristics of the analysis group
Sex Girls, n (%) Boys, n (%)
836 (50.6%) 817 (49.4%)
Age categories
3–o4 years 128 (15.3%) 123 (15.1%)
4–o5 years 147 (17.6%) 144 (17.6%)
5–o6 years 103 (12.3%) 106 (13.0%)
6–o7 years 125 (15.0%) 139 (17.0%)
7–o8 years 197 (23.6%) 180 (22.0%)
8–o9 years 136 (16.3%) 125 (15.3%)
Mean (s.d.) Mean (s.d.)
Age, years 6.09 (1.72) 6.05 (1.69)
Weight, kg 23.26 (6.25) 23.43 (6.28)
Height, cm 117.10 (11.99) 117.83 (12.09)
BMI, kgm− 2, unweighted 16.67 (1.96) 16.58 (1.89)
BMI, kgm− 2, weighted 16.03 (1.79) 16.11 (1.71)
BMI z-score, unweighted 0.57 (1.02) 0.47 (1.07)
BMI z-score, weighted 0.23 (0.99) 0.20 (1.02)
Abbreviation: BMI, body mass index.
Table 2. Correlations of FA proportion and age in normal weight
children
FA Girls (n= 523) Boys (n= 536)
r P-value r P-value
C16:0 − 0.026 0.547 − 0.129 0.003
C18:0 0.120 0.006 0.089 0.039
C24:0 0.063 0.148 0.132 0.002
C18:1n-9 − 0.264 o0.001 − 0.186 o0.001
C20:1n-9 − 0.141 0.001 − 0.099 0.022
C20:3n-9 − 0.144 o0.001 − 0.092 0.034
C18:2n-6 0.246 o0.001 0.171 o0.001
C22:5n-3 − 0.126 0.004 − 0.025 0.567
Sum MUFA − 0.259 o0.001 − 0.179 o0.001
Sum n-6 PUFA 0.210 o0.001 0.200 o0.001
Sum PUFA 0.178 o0.001 0.167 o0.001
Abbreviations: FA, fatty acid; MUFA, monounsaturated fatty acid; PUFA,
polyunsaturated fatty acid; r, Pearson’s correlation coefﬁcient.
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The FA composition is expressed as weight percentage of all FA
detected (% wt/wt) with a C16–C24 chain length excluding trans FA. The
following FA were measured: C16:0, C18:0, C20:0, C22:0, C24:0, C16:1,
C18:1n-9, C18:1n-7, C20:1, C22:1, C24:1, C20:3n-9, C18:2n-6, C18:3n-6,
C20:3n-6, C20:4n-6, C22:4n-6, C22:5n-6, C18:3n-3, C20:5n-3, C22:5n-3
and C22:6n-3. The desaturase indices were determined as follows:
SCD-1—C16:1n-7/16:0 (SCD-16), C18:1n-9/C18:0 (SCD-18); D6D—C20:3n-6/
C18:2n-6; D5D—C20:4n-6/C20:3n-6.
Statistical methods
Oversampling led to a high percentage of overweight children in the
sample. Therefore, weights were constructed to match the distribution of
Figure 2. Percentiles (% wt/wt) of selected FA in 3–8-year-old girls and boys calculated with GAMLSS.
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non-obese children from IDEFICS by sex and 1-year age groups. These
weights are used in all analyses and for results presented in the paper
except for analysis conducted in normal weight children.
Since the percentiles of most FA seemed to be similar across the age
groups Pearson correlation coefﬁcients were used to detect age
dependence in a subsample of normal weight boys and girls (n=1059,
536 boys, 523 girls). A cut-off of α= 0.01 and a correlation in both, boys and
girls, were used to decide which FA should be included in the further
analysis with generalized additive models for location scale and shape
(GAMLSS). Despite being correlated with age only in boys, C16:0 was also
included because of its high proportion in blood. Moreover, the most
important n-3 and n-6 PUFA and LC PUFA (except for C18:3n-3, C22:6n-3
and C20:4n-6 because no age dependence was seen) were included in
analysis with GAMLSS. We calculated percentile curves as a function of age
stratiﬁed by sex using the GAMLSS method as extension of the LMS
method. The LMS method models three parameters: the skewness (L)
Figure 2. (Continued)
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accounts for the deviation from a normal distribution using a Box–Cox
transformation, the median (M) accounts for the dependence of the
outcome variable on one explanatory variable and the coefﬁcient of
variation (S) accounts for the variation of data points around the mean and
adjusts for non-uniform dispersion. The GAMLSS method is able to model
more than one covariate and also other distributions. We used the gamlss
package (version 4.2–6) of the statistical software R (version 3.0.1).33
Different distributions, that is, the Box–Cox–Power–Exponential, Box–Cox t,
Box–Cox Cole and Green (BCCG), gamma, inverse Gaussian, logistic,
t family and normal distribution were ﬁtted to the observed distribution of
FA. Moreover, the inﬂuence of age on parameters of the considered
distributions were modelled as a constant, as a linear function or as a cubic
spline of the covariates.
Goodness-of-ﬁt was assessed by the Bayesian information criterion and
Q–Q plots to select the ﬁnal model including the ﬁtted distribution of FA
and the inﬂuence of the covariates on distribution parameters. Worm plots
were used as a diagnostic tool to assess whether adjustment for kurtosis
was required.34 Finally, curves for the 5th, 10th, 25th, 50th, 75th, 90th and
95th percentiles were calculated for C16:0, C18:0, C18:1n-9, C18:2n-6,
C20:5n-3 and C22:5n-3 on the basis of the model that showed the best
goodness-of-ﬁt.33,35 The best ﬁt in GAMLSS was reached for C16:0 and
C18:0 using the logistic distribution with parameters modelled as follows in
both sexes: μ linearly and log(σ) as a constant; for C18:1n-9 using the
gamma distribution with parameters modelled as follows: log(μ) linearly
and log(σ) as constant; for C18:2n-6 using a normal distribution with μ
modelled linearly and log(σ) modelled as a constant; for C20:5n-3 using the
BCCG distribution with parameters modelled as follows: μ linearly and log
(σ) and ν as constants. The best ﬁt for C22:5n-3 was reached using the
BCCG distribution without age dependence for boys and for girls using the
BCCG distribution where the parameters were modelled as follows:
μ linearly and log(σ) and ν as constants.
Percentiles of the other FA were not calculated with GAMLSS; the most
interesting of them were pooled for the age groups and are presented as
boxplots.
Sensitivity analysis using GAMLSS was conducted for all FA calculated
with GAMLSS regarding the inﬂuence of obesity. In addition, for these FA,
further GAMLSS analyses were conducted based on the data set including
obese children and children with diseases.
RESULTS
The characteristics of the study population with weighted and
unweighted body mass index and body mass index z-score are
presented in Table 1.
Table 3. Percentiles of FA composition (% wt/wt) calculated with GAMLSS
FA Age Percentile for girls FA Age Percentile for boys
5 10 25 50 75 90 95 5 10 25 50 75 90 95
C16:0 C16:0
3–o4 23.47 24.10 25.04 25.97 26.90 27.84 28.47 3–o4 23.67 24.30 25.21 26.13 27.04 27.96 28.58
4–o5 23.40 24.04 24.97 25.91 26.84 27.78 28.41 4–o5 23.56 24.18 25.10 26.01 26.93 27.84 28.47
5–o6 23.34 23.98 24.91 25.85 26.78 27.72 28.35 5–o6 23.44 24.06 24.98 25.90 26.81 27.73 28.35
6–o7 23.28 23.92 24.85 25.79 26.72 27.65 28.29 6–o7 23.32 23.95 24.86 25.78 26.70 27.61 28.24
7–o8 23.22 23.86 24.79 25.72 26.66 27.59 28.23 7–o8 23.21 23.83 24.75 25.66 26.58 27.50 28.12
8–o9 23.16 23.79 24.73 25.66 26.60 27.53 28.17 8–o9 23.09 23.72 24.63 25.55 26.47 27.38 28.00
C18:0 C18:0
3–o4 11.41 11.84 12.47 13.10 13.73 14.36 14.78 3–o4 11.79 12.18 12.75 13.31 13.88 14.45 14.83
4–o5 11.50 11.93 12.56 13.19 13.82 14.45 14.88 4–o5 11.83 12.22 12.79 13.35 13.92 14.49 14.87
5–o6 11.59 12.02 12.65 13.28 13.91 14.54 14.97 5–o6 11.87 12.26 12.82 13.39 13.96 14.52 14.91
6–o7 11.68 12.11 12.74 13.37 14.00 14.63 15.06 6–o7 11.91 12.30 12.86 13.43 14.00 14.56 14.95
7–o8 11.78 12.20 12.83 13.46 14.09 14.72 15.15 7–o8 11.95 12.34 12.90 13.47 14.04 14.60 14.99
8–o9 11.87 12.30 12.93 13.56 14.19 14.82 15.24 8–o9 11.99 12.38 12.94 13.51 14.08 14.64 15.03
C18:1n-9 C18:1n-9
3–o4 16.56 17.27 18.50 19.92 21.42 22.84 23.71 3–o4 16.13 16.84 18.03 19.35 20.67 21.85 22.56
4–o5 16.29 16.98 18.18 19.59 21.06 22.45 23.31 4–o5 15.91 16.62 17.81 19.13 20.45 21.64 22.35
5–o6 16.01 16.69 17.88 19.26 20.71 22.08 22.92 5–o6 15.69 16.40 17.59 18.91 20.23 21.42 22.13
6–o7 15.74 16.41 17.58 18.94 20.36 21.70 22.54 6–o7 15.47 16.18 17.37 18.69 20.01 21.20 21.91
7–o8 15.48 16.14 17.28 18.62 20.02 21.34 22.16 7–o8 15.25 15.96 17.15 18.47 19.79 20.98 21.69
8–o9 15.22 15.87 16.99 18.31 19.68 20.98 21.78 8–o9 15.03 15.75 16.93 18.25 19.57 20.76 21.47
C18:2n-6 C18:2n-6
3–o4 13.98 14.72 15.94 17.30 18.66 19.88 20.61 3–o4 14.10 14.83 16.05 17.41 18.76 19.98 20.71
4–o5 14.27 15.00 16.23 17.59 18.95 20.17 20.90 4–o5 14.32 15.05 16.27 17.62 18.98 20.20 20.93
5–o6 14.56 15.29 16.52 17.87 19.23 20.46 21.19 5–o6 14.54 15.27 16.49 17.84 19.20 20.42 21.15
6–o7 14.85 15.58 16.80 18.16 19.52 20.75 21.48 6–o7 14.75 15.48 16.70 18.06 19.41 20.63 21.37
7–o8 15.13 15.87 17.09 18.45 19.81 21.03 21.77 7–o8 14.97 15.70 16.92 18.28 19.63 20.85 21.58
8–o9 15.42 16.15 17.38 18.74 20.10 21.32 22.05 8–o9 15.19 15.92 17.14 18.49 19.85 21.07 21.80
C20:5n-3 C20:5n-3
3–o4 0.15 0.17 0.20 0.26 0.33 0.43 0.50 3–o4 0.15 0.17 0.20 0.26 0.33 0.42 0.48
4–o5 0.15 0.16 0.20 0.25 0.33 0.42 0.49 4–o5 0.15 0.16 0.20 0.25 0.32 0.41 0.47
5–o6 0.14 0.16 0.19 0.25 0.32 0.41 0.48 5–o6 0.14 0.16 0.20 0.25 0.32 0.40 0.46
6–o7 0.14 0.16 0.19 0.24 0.31 0.40 0.47 6–o7 0.14 0.16 0.19 0.24 0.31 0.39 0.45
7–o8 0.14 0.15 0.19 0.24 0.31 0.39 0.46 7–o8 0.14 0.15 0.19 0.24 0.30 0.38 0.44
8–o9 0.13 0.15 0.18 0.23 0.30 0.38 0.45 8–o9 0.13 0.15 0.18 0.23 0.30 0.38 0.44
C22:5n-3 C22:5n-3
3–o4 0.27 0.32 0.41 0.53 0.65 0.77 0.84 All 0.28 0.33 0.41 0.52 0.64 0.76 0.83
4–o5 0.27 0.32 0.40 0.51 0.63 0.75 0.82
5–o6 0.26 0.31 0.40 0.50 0.62 0.73 0.80
6–o7 0.25 0.30 0.39 0.49 0.61 0.72 0.79
7–o8 0.25 0.29 0.38 0.48 0.59 0.70 0.77
8–o9 0.24 0.29 0.37 0.47 0.58 0.68 0.75
Abbreviations: FA, fatty acid; GAMLSS, generalized additive models for location scale and shape.
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Table 4. Precentiles of FA composition (% wt/wt)
FA Age Percentile for girls FA Age Percentile for boys
5 10 25 50 75 90 95 5 10 25 50 75 90 95
Saturated FA (SFA) Saturated FA (SFA)
C20:0 C20:0
3–o4 0.42 0.42 0.47 0.52 0.58 0.63 0.65 3–o4 0.42 0.43 0.47 0.52 0.57 0.61 0.65
4–o5 0.42 0.43 0.48 0.52 0.57 0.61 0.65 4–o5 0.42 0.45 0.50 0.53 0.56 0.61 0.64
5–o6 0.41 0.44 0.47 0.51 0.58 0.62 0.68 5–o6 0.39 0.42 0.46 0.50 0.55 0.58 0.59
6–o7 0.42 0.44 0.48 0.52 0.57 0.60 0.62 6–o7 0.42 0.44 0.46 0.51 0.56 0.61 0.68
7–o8 0.43 0.44 0.48 0.52 0.57 0.60 0.64 7–o8 0.41 0.43 0.45 0.51 0.56 0.61 0.63
8–o9 0.41 0.43 0.47 0.53 0.58 0.62 0.64 8–o9 0.42 0.44 0.48 0.52 0.55 0.59 0.61
All 0.42 0.43 0.48 0.52 0.57 0.61 0.65 All 0.41 0.43 0.47 0.51 0.56 0.60 0.63
C22:0 C22:0
3–o4 1.37 1.49 1.65 1.80 1.95 2.09 2.23 3–o4 1.49 1.52 1.66 1.77 1.97 2.12 2.17
4–o5 1.47 1.56 1.67 1.84 1.97 2.08 2.18 4–o5 1.51 1.58 1.69 1.85 1.98 2.16 2.28
5–o6 1.44 1.49 1.65 1.82 2.01 2.18 2.29 5–o6 1.49 1.56 1.62 1.74 1.90 2.04 2.26
6–o7 1.43 1.47 1.66 1.81 1.97 2.14 2.19 6–o7 1.42 1.51 1.60 1.80 1.93 2.11 2.26
7–o8 1.52 1.56 1.63 1.78 1.96 2.08 2.19 7–o8 1.37 1.48 1.67 1.79 1.95 2.15 2.25
8–o9 1.54 1.58 1.69 1.82 1.96 2.10 2.18 8–o9 1.50 1.56 1.65 1.78 1.92 2.05 2.20
All 1.43 1.54 1.65 1.81 1.97 2.12 2.20 All 1.47 1.53 1.65 1.79 1.94 2.11 2.24
C24:0 C24:0
3–o4 2.33 2.42 2.63 2.90 3.31 3.50 3.66 3–o4 2.50 2.65 2.81 3.04 3.22 3.49 3.58
4–o5 2.33 2.47 2.79 3.03 3.30 3.47 3.56 4–o5 2.50 2.64 2.83 3.07 3.36 3.58 3.81
5–o6 2.37 2.51 2.78 3.02 3.38 3.59 3.76 5–o6 2.64 2.75 2.89 3.07 3.26 3.50 3.55
6–o7 2.44 2.61 2.76 3.03 3.31 3.49 3.66 6–o7 2.58 2.68 2.86 3.18 3.45 3.83 4.03
7–o8 2.48 2.57 2.77 3.02 3.29 3.52 3.81 7–o8 2.53 2.63 2.86 3.13 3.40 3.64 3.84
8–o9 2.54 2.64 2.86 3.06 3.31 3.56 3.73 8–o9 2.40 2.62 2.88 3.19 3.41 3.60 3.77
All 2.37 2.53 2.76 3.03 3.31 3.51 3.68 All 2.49 2.64 2.85 3.10 3.36 3.60 3.82
Total SFA Total SFA
3–o4 41.16 41.71 43.25 44.08 45.20 46.29 46.92 3–o4 42.52 42.73 43.78 44.80 46.24 47.08 47.35
4–o5 41.71 42.41 43.45 44.42 45.95 46.94 47.81 4–o5 42.07 42.36 43.46 44.70 45.81 47.23 47.60
5–o6 41.73 42.02 43.26 44.51 46.13 47.48 48.57 5–o6 42.04 42.78 43.44 44.54 45.62 47.40 47.94
6–o7 41.84 42.27 43.01 44.20 45.66 46.93 47.56 6–o7 41.64 42.33 43.37 44.79 45.60 47.25 49.56
7–o8 41.78 42.37 43.55 44.90 46.12 47.45 48.30 7–o8 41.90 42.50 43.48 44.75 45.83 47.18 47.78
8–o9 41.36 42.31 43.22 44.41 45.67 47.25 47.96 8–o9 41.46 41.89 43.26 44.31 46.04 46.88 47.49
All 41.55 42.19 43.26 44.42 45.85 47.14 47.82 All 41.81 42.44 43.45 44.66 45.88 47.15 47.87
MUFA MUFA
C16:1n-7 C16:1n-7
3–o4 0.76 0.90 1.05 1.28 1.55 1.85 2.06 3–o4 0.69 0.84 1.02 1.23 1.51 1.79 1.99
4–o5 0.77 0.86 0.99 1.18 1.46 1.79 1.93 4–o5 0.68 0.76 0.93 1.11 1.41 1.68 1.93
5–o6 0.71 0.82 0.95 1.20 1.50 1.83 2.30 5–o6 0.78 0.85 0.97 1.22 1.36 1.69 2.00
6–o7 0.70 0.85 0.99 1.20 1.47 1.72 1.89 6–o7 0.71 0.78 0.92 1.13 1.35 1.58 1.99
7–o8 0.72 0.74 0.94 1.20 1.43 1.68 1.84 7–o8 0.70 0.74 0.90 1.07 1.37 1.60 1.79
8–o9 0.69 0.79 0.95 1.18 1.38 1.61 2.06 8–o9 0.75 0.80 1.01 1.21 1.44 1.72 1.86
All 0.71 0.81 0.97 1.21 1.47 1.74 1.93 All 0.70 0.78 0.94 1.15 1.40 1.69 1.87
C18:1n-7 C18:1n-7
3–o4 1.23 1.33 1.47 1.65 1.85 2.16 2.54 3–o4 1.09 1.25 1.41 1.60 1.82 2.01 2.26
4–o5 1.26 1.30 1.40 1.58 1.74 1.97 2.32 4–o5 1.06 1.13 1.31 1.48 1.72 1.93 2.16
5–o6 1.08 1.21 1.41 1.61 1.91 2.04 2.21 5–o6 1.15 1.17 1.36 1.52 1.69 1.83 2.02
6–o7 1.15 1.23 1.40 1.57 1.79 2.05 2.13 6–o7 1.06 1.13 1.30 1.52 1.68 1.98 2.12
7–o8 1.13 1.24 1.36 1.55 1.77 2.00 2.15 7–o8 1.13 1.19 1.31 1.51 1.78 2.02 2.12
8–o9 1.04 1.17 1.34 1.55 1.73 2.06 2.20 8–o9 1.19 1.26 1.39 1.58 1.80 2.02 2.29
All 1.14 1.25 1.40 1.58 1.78 2.05 2.23 All 1.10 1.17 1.33 1.53 1.75 1.98 2.14
Total MUFA Total MUFA
3–o4 23.64 24.34 25.19 26.36 28.44 29.99 30.66 3–o4 21.88 22.66 24.43 26.06 27.61 29.26 29.73
4–o5 21.55 22.90 23.97 25.64 27.40 29.71 30.63 4–o5 21.73 22.15 23.34 25.40 26.78 27.85 28.34
5–o6 20.13 21.60 23.36 25.32 26.68 28.39 29.15 5–o6 21.94 22.41 23.53 24.84 26.12 27.72 28.40
6–o7 21.27 22.28 23.39 24.60 26.23 28.02 28.93 6–o7 21.12 22.12 22.94 24.17 25.77 27.28 27.83
7–o8 21.24 22.12 23.67 24.95 26.40 27.59 28.71 7–o8 21.29 21.71 23.00 24.70 26.08 27.80 28.48
8–o9 21.61 22.25 23.24 24.81 26.01 27.68 28.25 8–o9 21.01 21.93 23.49 25.11 26.37 27.32 27.78
All 21.40 22.36 23.75 25.24 26.80 28.50 29.78 All 21.36 21.97 23.29 24.89 26.41 27.82 28.76
n-9 PUFA n-9 PUFA
C20:3n-9 C20:3n-9
3–o4 0.04 0.05 0.06 0.08 0.10 0.14 0.17 3–o4 0.04 0.05 0.07 0.08 0.11 0.14 0.17
4–o5 0.03 0.04 0.06 0.08 0.10 0.14 0.16 4–o5 0.03 0.05 0.06 0.08 0.11 0.14 0.16
5–o6 0.04 0.05 0.06 0.08 0.10 0.14 0.17 5–o6 0.04 0.05 0.06 0.08 0.11 0.13 0.14
6–o7 0.04 0.05 0.06 0.08 0.10 0.12 0.15 6–o7 0.03 0.03 0.05 0.08 0.09 0.12 0.14
7–o8 0.04 0.04 0.06 0.08 0.10 0.12 0.14 7–o8 0.04 0.05 0.06 0.07 0.10 0.12 0.14
8–o9 0.03 0.04 0.05 0.06 0.08 0.12 0.13 8–o9 0.04 0.04 0.06 0.08 0.10 0.13 0.15
all 0.03 0.04 0.06 0.08 0.10 0.13 0.15 all 0.03 0.04 0.06 0.08 0.10 0.13 0.15
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Table. 4. (Continued )
FA Age Percentile for girls FA Age Percentile for boys
5 10 25 50 75 90 95 5 10 25 50 75 90 95
n-6 PUFA n-6 PUFA
C18:3n-6 C18:3n-6
3–o4 0.12 0.13 0.16 0.20 0.23 0.30 0.33 3–o4 0.13 0.15 0.17 0.21 0.27 0.34 0.39
4–o5 0.11 0.12 0.16 0.20 0.25 0.31 0.34 4–o5 0.11 0.14 0.18 0.21 0.28 0.34 0.39
5–o6 0.11 0.12 0.14 0.20 0.27 0.34 0.39 5–o6 0.13 0.14 0.18 0.21 0.27 0.34 0.38
6–o7 0.12 0.14 0.17 0.22 0.30 0.34 0.38 6–o7 0.12 0.13 0.16 0.21 0.26 0.34 0.38
7–o8 0.12 0.13 0.17 0.20 0.25 0.32 0.41 7–o8 0.12 0.14 0.18 0.21 0.29 0.37 0.41
8–o9 0.12 0.13 0.17 0.21 0.26 0.33 0.36 8–o9 0.11 0.13 0.16 0.22 0.25 0.33 0.37
all 0.12 0.13 0.16 0.20 0.26 0.32 0.36 all 0.12 0.14 0.17 0.21 0.27 0.34 0.40
C20:3n-6 C20:3n-6
3–o4 0.81 0.84 0.97 1.10 1.30 1.45 1.58 3–o4 0.80 0.89 0.96 1.15 1.35 1.48 1.54
4–o5 0.74 0.80 0.94 1.10 1.30 1.47 1.64 4–o5 0.84 0.90 1.02 1.18 1.42 1.55 1.67
5–o6 0.81 0.82 0.98 1.11 1.34 1.51 1.55 5–o6 0.85 0.93 1.09 1.24 1.44 1.58 1.68
6–o7 0.87 0.94 1.07 1.18 1.30 1.48 1.57 6–o7 0.85 0.92 1.06 1.18 1.39 1.53 1.70
7–o8 0.83 0.89 0.99 1.12 1.30 1.52 1.64 7–o8 0.92 0.98 1.08 1.22 1.40 1.53 1.59
8–o9 0.85 0.89 1.03 1.21 1.36 1.48 1.56 8–o9 0.88 0.95 1.08 1.26 1.43 1.60 1.77
all 0.80 0.85 0.99 1.13 1.31 1.49 1.59 all 0.85 0.91 1.04 1.21 1.40 1.54 1.66
C20:4n-6 C20:4n-6
3–o4 5.36 5.55 6.26 6.96 8.02 8.78 9.48 3–o4 4.89 5.31 6.24 7.32 7.97 8.53 9.05
4–o5 5.03 5.40 6.31 6.97 8.16 8.86 9.29 4–o5 5.43 5.87 6.56 7.37 8.44 9.07 9.38
5–o6 5.26 5.87 6.48 7.43 8.28 8.96 9.45 5–o6 4.93 5.62 6.44 7.54 8.21 9.00 9.20
6–o7 5.28 5.71 6.60 7.54 8.35 8.89 9.29 6–o7 5.14 5.93 6.92 7.70 8.68 9.51 10.08
7–o8 5.01 5.42 6.15 7.06 8.05 8.81 9.14 7–o8 5.69 5.88 6.58 7.35 8.15 8.91 9.22
8–o9 4.77 5.35 6.33 7.25 8.40 8.93 9.55 8–o9 4.87 5.67 6.61 7.57 8.43 9.29 9.65
all 5.13 5.47 6.28 7.21 8.18 8.87 9.39 all 5.14 5.69 6.55 7.48 8.32 9.02 9.39
C22:4n-6 C22:4n-6
3–o4 0.65 0.69 0.78 0.95 1.14 1.30 1.42 3–o4 0.57 0.62 0.85 1.01 1.19 1.37 1.46
4–o5 0.60 0.66 0.80 0.96 1.13 1.38 1.47 4–o5 0.60 0.72 0.84 1.02 1.21 1.35 1.55
5–o6 0.57 0.68 0.79 1.00 1.20 1.34 1.46 5–o6 0.59 0.70 0.86 1.08 1.22 1.34 1.45
6–o7 0.66 0.73 0.85 1.06 1.23 1.44 1.50 6–o7 0.72 0.75 0.88 1.08 1.36 1.49 1.53
7–o8 0.59 0.65 0.76 0.96 1.16 1.32 1.36 7–o8 0.67 0.75 0.88 1.03 1.22 1.43 1.51
8–o9 0.57 0.66 0.90 1.04 1.22 1.44 1.57 8–o9 0.56 0.68 0.87 1.07 1.28 1.46 1.62
All 0.59 0.66 0.80 0.99 1.17 1.35 1.46 All 0.60 0.71 0.86 1.05 1.24 1.42 1.51
Total n-6 PUFA Total n-6 PUFA
3–o4 23.20 24.05 24.95 27.04 28.61 29.74 30.30 3–o4 22.19 23.45 25.33 26.79 28.80 30.26 31.21
4–o5 22.70 24.17 25.71 27.61 29.26 30.69 31.52 4–o5 24.13 25.14 26.16 27.49 29.64 31.78 32.60
5–o6 23.11 24.15 26.08 28.09 30.11 31.62 32.92 5–o6 23.56 24.38 26.59 28.47 29.93 31.43 31.92
6–o7 24.11 25.17 26.66 28.46 30.61 31.74 32.33 6–o7 24.41 24.98 26.68 28.70 30.33 31.89 32.63
7–o8 24.50 25.15 26.39 28.36 30.05 31.42 32.04 7–o8 24.64 25.47 26.89 28.70 30.23 31.72 32.42
8–o9 23.70 25.13 26.94 28.83 30.42 31.52 32.15 8–o9 24.02 25.22 27.05 28.73 30.21 31.89 32.97
All 23.53 24.49 26.10 28.07 29.87 31.32 31.98 All 23.73 24.62 26.22 28.31 29.88 31.58 32.35
Total n-6 LC PUFA Total n-6 LC PUFA
3–o4 7.20 7.47 8.31 9.38 10.75 11.43 12.34 3–o4 6.51 7.03 8.34 9.92 10.82 11.51 12.10
4–o5 6.67 7.41 8.30 9.31 10.90 11.78 12.40 4–o5 7.17 7.82 8.66 9.95 11.28 12.26 12.75
5–o6 6.97 7.62 8.58 9.97 10.98 11.91 12.39 5–o6 6.70 7.32 8.78 10.21 11.10 12.13 12.35
6–o7 7.27 7.81 8.70 10.03 11.00 12.09 12.39 6–o7 7.18 7.83 9.14 10.27 11.62 12.69 13.30
7–o8 6.75 7.24 8.15 9.47 10.91 11.72 12.03 7–o8 7.60 7.93 8.82 10.02 10.99 12.00 12.29
8–o9 6.71 7.23 8.54 9.85 11.15 12.11 12.78 8–o9 7.01 7.96 8.93 10.30 11.59 12.36 12.90
All 6.86 7.34 8.40 9.64 10.95 11.88 12.40 All 6.98 7.57 8.74 10.04 11.19 12.21 12.65
n-3 PUFA n-3 PUFA
C18:3n-3 C18:3n-3
3–o4 0.11 0.12 0.15 0.21 0.26 0.33 0.37 3–o4 0.10 0.11 0.14 0.19 0.24 0.31 0.36
4–o5 0.11 0.12 0.14 0.20 0.26 0.35 0.39 4–o5 0.11 0.13 0.15 0.20 0.26 0.36 0.40
5–o6 0.11 0.12 0.13 0.19 0.26 0.31 0.33 5–o6 0.10 0.11 0.14 0.19 0.23 0.31 0.38
6–o7 0.10 0.11 0.14 0.18 0.25 0.32 0.39 6–o7 0.10 0.11 0.13 0.17 0.23 0.28 0.32
7–o8 0.09 0.10 0.13 0.19 0.27 0.32 0.34 7–o8 0.10 0.11 0.13 0.18 0.25 0.31 0.35
8–o9 0.10 0.10 0.13 0.18 0.25 0.31 0.37 8–o9 0.10 0.12 0.14 0.18 0.23 0.27 0.31
All 0.10 0.11 0.14 0.19 0.26 0.32 0.38 All 0.10 0.11 0.14 0.18 0.24 0.31 0.37
C22:6n-3 C22:6n-3
3–o4 0.59 0.68 0.86 1.13 1.46 1.71 1.91 3–o4 0.58 0.69 0.84 1.08 1.46 1.66 1.85
4–o5 0.53 0.59 0.75 1.09 1.35 1.61 1.82 4–o5 0.64 0.72 1.02 1.26 1.49 1.69 1.94
5–o6 0.63 0.76 0.95 1.18 1.47 1.79 2.19 5–o6 0.56 0.70 0.95 1.17 1.40 1.70 1.96
6–o7 0.51 0.63 0.93 1.17 1.48 1.82 2.03 6–o7 0.52 0.65 0.84 1.18 1.55 2.01 2.33
7–o8 0.43 0.50 0.71 1.02 1.31 1.59 1.78 7–o8 0.56 0.63 0.80 1.02 1.31 1.59 1.75
8–o9 0.48 0.63 0.84 1.13 1.44 1.77 1.92 8–o9 0.52 0.63 0.84 1.13 1.41 1.75 1.87
All 0.50 0.59 0.82 1.11 1.40 1.71 1.92 All 0.53 0.65 0.85 1.13 1.44 1.73 1.94
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Table. 4. (Continued )
FA Age Percentile for girls FA Age Percentile for boys
5 10 25 50 75 90 95 5 10 25 50 75 90 95
Total n-3 PUFA Total n-3 PUFA
3–o4 1.37 1.49 1.80 2.17 2.66 3.14 3.29 3–o4 1.34 1.52 1.70 2.01 2.48 3.03 3.18
4–o5 1.13 1.32 1.66 2.07 2.49 2.81 3.17 4–o5 1.23 1.50 1.93 2.29 2.72 3.08 3.44
5–o6 1.45 1.53 1.81 2.11 2.63 3.01 3.67 5–o6 1.25 1.53 1.82 2.12 2.58 3.13 3.33
6–o7 1.24 1.37 1.65 2.18 2.53 2.97 3.18 6–o7 1.20 1.39 1.71 2.17 2.61 3.28 3.59
7–o8 1.13 1.22 1.46 1.94 2.37 2.83 3.00 7–o8 1.26 1.36 1.65 2.03 2.40 2.68 3.02
8–o9 1.26 1.43 1.60 2.07 2.60 3.00 3.22 8–o9 1.17 1.29 1.69 2.17 2.56 2.93 3.16
All 1.19 1.34 1.62 2.09 2.52 2.97 3.21 All 1.21 1.39 1.73 2.12 2.53 3.04 3.32
Total n-3 LC PUFA Total n-3 LC PUFA
3–o4 1.22 1.32 1.59 1.94 2.52 2.85 3.05 3–o4 1.18 1.32 1.50 1.81 2.32 2.81 2.92
4–o5 0.96 1.13 1.41 1.87 2.27 2.57 2.93 4–o5 1.12 1.29 1.71 2.09 2.44 2.79 3.18
5–o6 1.23 1.35 1.61 1.97 2.39 2.86 3.41 5–o6 1.06 1.28 1.67 1.94 2.39 2.89 3.21
6–o7 1.04 1.18 1.50 1.98 2.37 2.76 2.92 6–o7 1.01 1.23 1.56 1.99 2.42 3.04 3.38
7–o8 0.91 1.02 1.24 1.80 2.15 2.55 2.86 7–o8 1.10 1.19 1.49 1.82 2.19 2.49 2.85
8–o9 1.06 1.26 1.45 1.90 2.39 2.78 2.96 8–o9 0.99 1.16 1.49 1.95 2.38 2.73 2.94
All 0.99 1.15 1.43 1.91 2.33 2.71 2.97 All 1.04 1.21 1.54 1.94 2.35 2.80 3.04
Ratios/indices Ratios/indices
n-6/n-3 n-6/n-3
3–o4 8.67 9.00 10.17 12.28 15.13 17.97 20.11 3–o4 8.12 8.84 10.94 13.38 15.81 18.33 21.98
4–o5 8.79 9.59 11.03 13.35 16.71 20.15 23.35 4–o5 8.50 8.64 10.40 12.50 14.53 18.57 22.32
5–o6 8.09 9.05 11.01 13.00 15.77 17.71 20.62 5–o6 9.12 9.31 11.11 13.20 15.39 18.89 20.71
6–o7 9.31 9.73 11.56 13.09 16.73 20.35 21.18 6–o7 8.27 9.30 11.15 13.22 16.71 20.78 22.03
7–o8 9.50 10.39 11.91 14.80 18.73 22.57 25.52 7–o8 9.45 10.32 12.07 14.00 17.24 20.78 22.33
8–o9 8.83 9.40 11.63 14.09 17.07 19.74 22.94 8–o9 9.44 10.08 11.19 13.31 17.30 21.22 23.21
All 8.67 9.48 11.16 13.46 16.73 20.37 22.97 All 8.49 9.33 11.11 13.28 16.36 20.37 22.19
C20:4n-6/C20:3n6
(D5D)
C20:4n-6/C20:3n6
(D5D)
3–o4 4.63 4.85 5.17 6.26 7.59 8.70 9.15 3–o4 4.68 4.98 5.41 6.05 7.16 8.27 8.72
4–o5 4.59 4.86 5.59 6.21 7.33 8.54 9.17 4–o5 4.16 4.65 5.46 6.31 7.31 7.85 8.44
5–o6 4.51 4.76 5.63 6.40 7.59 8.64 9.64 5–o6 4.33 4.59 5.21 5.82 6.79 7.51 8.02
6–o7 4.31 4.80 5.69 6.27 7.20 7.96 8.40 6–o7 4.29 4.86 5.50 6.41 7.38 8.12 8.49
7–o8 4.22 4.76 5.42 6.27 7.21 7.98 8.54 7–o8 4.53 4.86 5.22 5.96 6.77 7.68 8.23
8–o9 4.20 4.63 5.41 6.17 6.77 7.83 8.80 8–o9 4.21 4.60 5.19 6.11 6.75 7.59 7.87
All 4.31 4.73 5.45 6.24 7.22 8.31 9.05 All 4.28 4.72 5.33 6.08 7.03 7.87 8.35
C20:3n-6/C18:2n-6
(D6D)
C20:3n-6/C18:2n-6
(D6D)
3–o4 0.05 0.05 0.06 0.07 0.08 0.09 0.10 3–o4 0.05 0.05 0.06 0.07 0.08 0.09 0.10
4–o5 0.04 0.04 0.05 0.06 0.08 0.09 0.09 4–o5 0.05 0.05 0.06 0.07 0.08 0.09 0.10
5–o6 0.04 0.04 0.05 0.06 0.07 0.09 0.09 5–o6 0.05 0.05 0.06 0.07 0.08 0.09 0.10
6–o7 0.05 0.05 0.06 0.06 0.07 0.08 0.10 6–o7 0.05 0.05 0.06 0.07 0.08 0.09 0.10
7–o8 0.04 0.05 0.05 0.06 0.07 0.09 0.09 7–o8 0.05 0.05 0.06 0.07 0.08 0.09 0.10
8–o9 0.04 0.05 0.06 0.06 0.07 0.08 0.09 8–o9 0.05 0.05 0.06 0.07 0.08 0.10 0.11
All 0.04 0.05 0.05 0.06 0.07 0.09 0.09 All 0.05 0.05 0.06 0.07 0.08 0.09 0.10
C16:1n-7/C16:0
(SCD-16)
C16:1n-7/C16:0
(SCD-16)
3–o4 0.03 0.04 0.04 0.05 0.06 0.07 0.08 3–o4 0.03 0.03 0.04 0.05 0.06 0.07 0.07
4–o5 0.03 0.03 0.04 0.05 0.06 0.07 0.07 4–o5 0.03 0.03 0.04 0.04 0.06 0.06 0.07
5–o6 0.03 0.03 0.04 0.05 0.06 0.07 0.08 5–o6 0.03 0.03 0.04 0.05 0.05 0.06 0.07
6–o7 0.03 0.03 0.04 0.05 0.06 0.07 0.07 6–o7 0.03 0.03 0.04 0.04 0.05 0.06 0.07
7–o8 0.03 0.03 0.04 0.05 0.05 0.07 0.07 7–o8 0.03 0.03 0.04 0.04 0.05 0.06 0.07
8–o9 0.03 0.03 0.04 0.05 0.05 0.06 0.07 8–o9 0.03 0.03 0.04 0.05 0.05 0.07 0.07
All 0.03 0.03 0.04 0.05 0.06 0.07 0.07 All 0.03 0.03 0.04 0.04 0.05 0.06 0.07
C18:1n-9/C18:0
(SCD-18)
C18:1n-9/C18:0
(SCD-18)
3–o4 1.26 1.32 1.42 1.53 1.72 1.90 1.98 3–o4 1.17 1.24 1.35 1.49 1.64 1.73 1.82
4–o5 1.13 1.23 1.37 1.48 1.60 1.76 1.89 4–o5 1.16 1.22 1.32 1.41 1.57 1.68 1.80
5–o6 1.07 1.14 1.28 1.39 1.62 1.76 1.81 5–o6 1.12 1.18 1.30 1.40 1.54 1.63 1.72
6–o7 1.11 1.18 1.28 1.39 1.55 1.71 1.78 6–o7 1.08 1.13 1.24 1.36 1.49 1.57 1.67
7–o8 1.10 1.13 1.25 1.39 1.50 1.68 1.73 7–o8 1.05 1.12 1.23 1.37 1.49 1.61 1.68
8–o9 1.08 1.18 1.26 1.39 1.51 1.61 1.72 8–o9 1.12 1.16 1.28 1.39 1.53 1.65 1.72
All 1.10 1.18 1.30 1.44 1.57 1.74 1.85 All 1.10 1.16 1.28 1.40 1.53 1.66 1.74
Abbreviations: D5D, delta-5-desaturase index; D6D, delta-6-desaturase index; FA, fatty acid; MUFA, monounsaturated FA; PUFA, polyunsaturated FA; n-6/n-3,
ratio of sums of all n-6 PUFA/n-3 PUFA; SCD, stearoyl-CoA desaturase; SCD-16, C16:1n-7/C16:0 ratio; SCD-18, C18:1n-9/C18:0 ratio; SFA, saturated FA.
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Signiﬁcant but weak correlations of the FA proportion with age
were seen for C18:1n-9, C18:2n-6 and sums of monounsaturated
FA, PUFA and n-6 PUFA in both, girls and boys. Some age
dependencies were only seen in either boys or in girls (Table 2).
C18:0 and C18:2n-6 showed a positive trend with age, whereas
this trend was negative for C16:0, C18:1n-9 and C20:5n-3 in both
boys and girls (Figure 2). C22:5n-3 decreased in girls but not in
boys. The corresponding percentiles based on GAMLSS are shown
in Table 3. Only pooled percentiles are shown for C22:5n-3 in boys
because no age-dependence was detected. Percentiles of the
other FA, total saturated, unsaturated, polyunsaturated FA, n-6/n-3
ratio and important indices of enzyme activity stratiﬁed by sex and
age as well as pooled for age groups are shown in Table 4. As
most of those FA are not or only weakly correlated with age,
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Figure 3 shows boxplots for the pooled percentage of selected FA
in 3–8-year-old boys and girls.
Most FA levels were pretty similar in boys and girls but the
median FA proportions of C20:3n-6, C20:4n-6 and C22:4n-6
seemed to be slightly higher in boys than in girls (Table 4 and
Figure 3).
Sensitivity analysis regarding the inﬂuence of obesity accord-
ing to common deﬁnitions from the World Health
Organization,36,37 Centers for Disease Control,38 and Cole and
Lobstein31 showed only slightly deviating percentile curves
when obese children were included (Supplementary Figure A).
For the sake of completeness and to allow comparisons with
other studies, percentiles of selected FA for the total study
sample (including obese children and children with diseases)
are shown in Supplementary Figure B and Supplementary
Table A. They hardly differ from the percentiles in Figure 2 with
the exception that the positive trend of C18:0 with age
disappeared.
DISCUSSION
We have presented the whole-blood FA distributions for
apparently healthy 3–8-year-old European girls and boys, and
important indices as marker of enzyme activity that can be used as
reference values in clinical and epidemiological studies. To our
knowledge, the present study is the ﬁrst to provide data on the FA
composition of a large sample of European children.
Whole blood as the source of FA analysis
We used whole blood for FA analysis as that can easily be
obtained from a drop of blood from the ﬁngertip or venipuncture.
A rapid and simple analysis method was used that allows FA
measurement in large study populations and that was validated
by several laboratories.32,39,40 Conventionally, FA were measured
in plasma or serum reﬂecting short-term fat intake or in red blood
cells (RBC) reﬂecting long-term fat intake. Whole-blood FA derive
from both, plasma (54% by volume) and circulating cells (46% by
volume), the latter predominantely consisting of RBC.41 As cell
membranes are comprised mainly of phospholipids that are
particularly rich in LC PUFA such as C20:5n-3 and C22:6n-3 whole
blood contains higher LC PUFA and lower PUFA percentages than
serum.32 This is in line with data showing that the C20:5n-3 and
C22:6n-3 content of the whole blood is highly correlated with that
of RBC.42 Whole blood includes FA from all lipid classes with
phospholipids of plasma and RBC being the main contributors of
the FA amount and proﬁle. Therefore, whole blood provides a
balanced picture of the FA status and is representative for the
total FA pool.39 Several studies conﬁrmed that whole blood
reﬂects the dietary FA intake and is a suitable marker for long-term
essential FA intake. This is also true for n-3 FA that are reasonably
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stable in fasting whole blood and can therefore be used to
determine n-3 FA status.4,32,43
Montgomery et al.44 also used whole blood samples for FA
measurement in 493 school children aged 7–9 years from
Oxfordshire, UK, and found similar percentages of n-6 FA but
markedly higher n-3 FA than in our sample. Whole blood FA have
also been measured in a nested case–ontrol study of the
Physicians’ Health Study showing an 72% and 81% lower risk of
sudden death in men with n-3 LC PUFA levels in the upper third
and fourth quartiles, respectively, compared with the lowest
quartile.45 The values of n-3 and n-6 PUFA reported are
considerably higher than in our study. Different values compared
with our study may be explainable by differences in the analytical
method and the range of FA measured. In addition, in the latter
study they can also result from the higher age of the participants
and an additional extraction step in the analysis compared with
our method.45 Furthermore, the dietary intake may have been
higher in both more homogenous study populations,44,45 whereas
our sample is pretty heterogeneous and represents the FA
composition of children with various dietary habits from
throughout Europe.
Age dependence of FA
In the subsample of normal weight children, only a few FA were
(weakly) associated with age. The analysis using GAMLSS revealed
a negative association of C18:1n-9 and a positive association of
C18:2n-6 and C18:0 with age.
Accordingly, in a large German sample of 2- and 6-year-old boys
and girls, no major age dependencies were observed in the FA
composition of serum glycerophospholipids. In line with the trend
across the age groups in our sample, C18:2n-6 was slightly higher
and C18:1n-9 slightly lower in 6- compared with 2-year-old
children.29
In the sample of 493 school children aged 7–9 years, children of
the lowest age group (7 years) had higher C22:5n-3, C20:4n-6 and
C18:2n-6 than older children.44 Our data conﬁrmed a decreasing
trend of C22:5n-3 with age in girls but we found C18:2n-6 to
increase with age and no age dependence for C20:4n-6.
Harris et al.4 measured erythrocyte FA in 160 000 patients aged
from 10 to 99 years and reported an increase of C22:6n-3 and
C20:5n-3 and a decrease of C18:2n-6 over the ﬁrst seven decades.
Total saturated FA, total PUFA, C20:4n-6 and C18:3n-3 remained
almost the same across all ages. A positive age trend of C18:2n-6
or a negative trend of C20:5n-3, as observed in our sample, was
not reported by Harris et al., but their sample may not be
comparable to ours because of older age groups and the selection
of patients whose blood samples were analysed for diagnostic
purposes.
In a Hungarian sample of 188 healthy subjects including
newborns, infants, children and young adults C18:2n-6 was
positively associated with age28 conﬁrming our results and those
from others,29 whereas C18:0, C20:4n-6 and C18:3n-3 were higher
in children than in young adults.28 In contrast to our ﬁndings,
C16:0, C20:5n-3, C22:6n-3, n-3 PUFA and n-3 LC PUFA showed a
positive trend with age, whereas C20:4n-6, n-6 PUFA and n-6 LC
PUFA showed a negative trend.28
Recently, data of whole-blood FA composition of 2–9-year-old
children of the Italian IDEFICS cohort were compared with
neonates, adults and elderly from other Italian samples.40
C22:6n-3 levels of the 2–9-year-old children were found to be
much lower as compared with neonates, adults and elderly. The
authors concluded that this resulted either from lower intakes or
from the fact that the rates of utilisation and resulting
physiological requirements are higher than in adults. C18:3n-3,
C18:2n-6, n-6 PUFA and total PUFA were lowest in neonates and
increased progressively in children and adults, whereas mono-
unsaturated FA in children were signiﬁcantly lower than in adults
and neonates. A positive trend of C18:2n-6, n-6 PUFA and total
PUFA with age is in line with our data but we observed an inverse
association of monounsaturated FA with age.
Whereas the Italian IDEFICS subsample included a high
proportion of overweight and obese children,40 we constructed
and applied weights to correct for the oversampling because
studies showed an altered FA composition in obese children,46 for
example, C22:6n-3 levels being inversely associated with the body
mass index.16 However, our sensitivity analysis regarding the
inﬂuence of obesity showed only minor differences in the
percentile curves when obese children were included.
Sex differences of FA
In our sample, C20:3n-6, C20:4n-6 and C22:4n-6 seemed to be
slightly higher in boys than in girls. In British school children, boys
not only had higher mean C20:3n-6 and C20:4n-6 but also higher
C22:5n-3 and C22:6n-3 than girls.44 In a large German cohort—in
line with our results—6-year-old boys had higher C20:3n-6 and
C22:4n-6 than girls.29
In Italian samples, among the main n-6 and n-3 PUFA only
C18:2n-6 was signiﬁcantly different in all groups (neonates,
children, adults and elderly) being higher in females than in
males.40
Ratio and indices of FA percentages
We also provide the n-6/n-3 ratio and indices of enzyme activity
that can be used as reference values for further studies. Ratios of
n-6/n-3 or n-3/n-6 FA have been used in several studies to assess
associations between the FA composition and health outcome or
corresponding surrogate markers.47–50 Enzyme activity indices
estimated from product/precursor ratios for SCD-1 (SCD-16,
SCD-18), the rate-limiting enzymes in the biosynthesis of C16:1n-
7 and C18:1n-9, and for D6D and D5D, required in the production
of eicosanoids from C18:2n-6 and C18:3n-3, are important factors
of the blood FA composition besides dietary intake. Studies have
shown that obesity and metabolic syndrome are associated with
high SCD-1 and D6D indices, and low D5D index.15,16,26 However,
it is important to keep in mind that these activity indices were
only estimated and not directly measured. Thus, our results need
to be interpreted with caution because they reﬂect not only the
inﬂuence of genetics including single-nucleotide polymorphisms
and haplotypes but also the environmental and dietetic factors,
such as the FA and carbohydrate intake, that can alter the FA
composition and the desaturase activities.
Strengths and limitations
This is the ﬁrst study that shows FA reference values for a large
European sample of 3.0–8.9-year-old children. We have also
reported the estimated enzyme activities that have not been
provided before. However, as the dietary FA intakes were not
analysed, we do not know whether the indicated reference ranges
for PUFA correspond to dietary intakes that are in line with the
recommendations.
CONCLUSION
Reported associations and causal relationship between the LC
PUFA status and health-related outcomes increase the interest in
FA determination. Therefore, the presented FA reference ranges of
European children may be useful for the interpretation of the
whole-blood FA composition. They provide a basis for comparison
in epidemiological and clinical studies, and may also be used as an
orientation for clinical practice in future. As the dietary intake does
not meet the recommended daily amount for total PUFA and
particularly not for n-3 LC PUFA in children and adolescents,51 the
presented reference values for PUFA do not allow conclusions
with regard to health outcomes. Prospective studies relating FA
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level to health outcomes are needed to determine target values of
blood PUFA and particularly n-3 LC PUFA composition for primary
and secondary prevention.
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